Market Place
Sourcing Support
VBI Vaccines Issues Voluntary Recall of PreHevbrio Vaccine
15 Nov 2024 //
BUSINESSWIRE
VBI Vaccines secures court protection as it restructures, seeks buyer(s)
30 Jul 2024 //
FIERCE BIOTECH
VBI Vaccines Announces AGM Results
25 Jun 2024 //
BUSINESSWIRE
VBI`s VBI-1901 Tumor Response Data In Recurrent Glioblastoma Phase 2b
29 May 2024 //
BUSINESSWIRE
VBI Presents VBI-1901 Interim Glioblastoma Phase 2b At ASCO
22 May 2024 //
BUSINESSWIRE
VBI Vaccines Reports First Quarter 2024 Financial Results
15 May 2024 //
BUSINESSWIRE
VBI Vaccines Reports Full Year 2023 Financial Results
16 Apr 2024 //
BUSINESSWIRE
VBI $2M Registered Direct Offering Per Nasdaq
11 Apr 2024 //
BUSINESSWIRE
VBI Vaccines Announces $2M Direct Offering
09 Apr 2024 //
BUSINESSWIRE
VBI Announces Strategic Partnership with Canadian Govt to for Vaccine Platform
02 Apr 2024 //
BUSINESSWIRE
VBI Vaccines shrinks `long-term burn` with $33M Brii Bio deal
14 Feb 2024 //
FIERCE PHARMA
VBI Vaccines Presents Biomarker Data from Phase 1/2a Study of VBI-1901
20 Nov 2023 //
BUSINESSWIRE
VBI Vaccines Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
BUSINESSWIRE
VBI Vaccines Expands Proprietary Technology Platforms
26 Oct 2023 //
BUSINESSWIRE
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901
27 Sep 2023 //
BUSINESSWIRE
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901
07 Sep 2023 //
BUSINESSWIRE
VBI Vaccines Partner Brii Announces Results of Phase 2 Study Evaluating BRII-179
06 Sep 2023 //
BUSINESSWIRE
VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option
24 Jul 2023 //
BUSINESSWIRE
VBI Vaccines Announces PreHevbri is Available in Netherlands and Belgium
19 Jul 2023 //
PRESS RELEASE
Brii pays VBI $15M for global rights to hepB program and more
06 Jul 2023 //
FIERCE BIOTECH
VBI Vaccines Announces Pricing of $18 Million Public Offering
06 Jul 2023 //
BUSINESSWIRE
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership
05 Jul 2023 //
BUSINESSWIRE
VBI Vaccines Announces Proposed Concurrent Public Offering of Common Shares
05 Jul 2023 //
BUSINESSWIRE
VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom
15 Jun 2023 //
BUSINESSWIRE
VBI Vaccines Announces Poster Presentation at EASL 2023
07 Jun 2023 //
BUSINESSWIRE
VBI Vaccines Reports First Quarter 2023 Financial Results
15 May 2023 //
BUSINESSWIRE
VBI Vaccines pares down pipeline, staff to focus on hepatitis B
04 Apr 2023 //
FIERCE BIOTECH
VBI Vaccines Reports Full Year 2022 Financial Results
13 Mar 2023 //
BUSINESSWIRE
VBI to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat
23 Feb 2023 //
BUSINESSWIRE
VBI Announces Presentation of PII Evaluating Combination of VBI-2601 & BRII-835
15 Feb 2023 //
BUSINESSWIRE
